← All trials
NCT06361446
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 29, 2024
- Primary completion
- Mar 30, 2025
- Completion date
- Apr 20, 2025
- First posted
- Apr 11, 2024
- Last posted
- Apr 23, 2024
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kafrelsheikh UniversityLead sponsor
- Kafrelsheikh UniversitySponsor investigator
- Kafrelsheikh UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.